Corvus Pharmaceuticals, Inc.

NasdaqGM:CRVS 株式レポート

時価総額:US$591.1m

Corvus Pharmaceuticals 将来の成長

Future 基準チェック /26

Corvus Pharmaceuticalsは、7.1%と76.9%でそれぞれ年率7.1%で利益と収益が成長すると予測される一方、EPSはgrowで14.9%年率。

主要情報

7.1%

収益成長率

14.9%

EPS成長率

Biotechs 収益成長27.3%
収益成長率76.9%
将来の株主資本利益率n/a
アナリストカバレッジ

Low

最終更新日22 Oct 2024

今後の成長に関する最新情報

Recent updates

Corvus Pharmaceuticals: Soquelitinib's High Stakes In PTCL Therapy

Sep 02

Will Corvus Pharmaceuticals (NASDAQ:CRVS) Spend Its Cash Wisely?

Mar 06
Will Corvus Pharmaceuticals (NASDAQ:CRVS) Spend Its Cash Wisely?

Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation

Oct 23
Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation

Is Corvus Pharmaceuticals (NASDAQ:CRVS) In A Good Position To Invest In Growth?

May 16
Is Corvus Pharmaceuticals (NASDAQ:CRVS) In A Good Position To Invest In Growth?

Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation

Dec 05
Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation

Corvus' partner Angel Pharma gets nod to start phase 1/1b trial of cancer therapy in China

Sep 26

We're Keeping An Eye On Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Rate

Aug 14
We're Keeping An Eye On Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Rate

Companies Like Corvus Pharmaceuticals (NASDAQ:CRVS) Are In A Position To Invest In Growth

Apr 05
Companies Like Corvus Pharmaceuticals (NASDAQ:CRVS) Are In A Position To Invest In Growth

We're Hopeful That Corvus Pharmaceuticals (NASDAQ:CRVS) Will Use Its Cash Wisely

Dec 15
We're Hopeful That Corvus Pharmaceuticals (NASDAQ:CRVS) Will Use Its Cash Wisely

Checking In On Corvus Pharmaceuticals

Dec 10

Corvus: Surging On AstraZeneca CD73 Success With Key Data Readout Looming

Sep 22

We Think Corvus Pharmaceuticals (NASDAQ:CRVS) Can Afford To Drive Business Growth

Aug 26
We Think Corvus Pharmaceuticals (NASDAQ:CRVS) Can Afford To Drive Business Growth

Corvus Pharmaceuticals initiated buy at Cantor with a Street-high target

May 27

Is Corvus Pharmaceuticals (NASDAQ:CRVS) In A Good Position To Deliver On Growth Plans?

May 08
Is Corvus Pharmaceuticals (NASDAQ:CRVS) In A Good Position To Deliver On Growth Plans?

The Co-Founder of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), Richard Miller, Just Bought 8.5% More Shares

Feb 19
The Co-Founder of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), Richard Miller, Just Bought 8.5% More Shares

Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation

Feb 07
Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation

Here's What Corvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) Shareholder Ownership Structure Looks Like

Dec 16
Here's What Corvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) Shareholder Ownership Structure Looks Like

Corvus Pharmaceuticals EPS misses by $0.06

Oct 29

業績と収益の成長予測

NasdaqGM:CRVS - アナリストの将来予測と過去の財務データ ( )USD Millions
日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数
12/31/20265-47-40N/A5
12/31/20251-37-29N/A5
12/31/2024N/A-25-22N/A5
6/30/2024N/A-23-21-21N/A
3/31/2024N/A-25-21-21N/A
12/31/2023N/A-27-24-24N/A
9/30/2023N/A-30-26-26N/A
6/30/2023N/A-39-28-28N/A
3/31/2023N/A-41-29-29N/A
12/31/2022N/A-41-27-27N/A
9/30/2022N/A-41-27-26N/A
6/30/2022N/A-37-28-28N/A
3/31/2022N/A-40-34-34N/A
12/31/2021N/A-43-37-37N/A
9/30/2021N/A-7-38-38N/A
6/30/2021N/A-6-37-37N/A
3/31/2021N/A-5-34-34N/A
12/31/2020N/A-6-35-35N/A
9/30/2020N/A-44-35-35N/A
6/30/2020N/A-46-38-38N/A
3/31/2020N/A-48-38-38N/A
12/31/2019N/A-47-37-37N/A
9/30/2019N/A-46-37-37N/A
6/30/2019N/A-46-38-37N/A
3/31/2019N/A-44-39-39N/A
12/31/2018N/A-47-41-41N/A
9/30/2018N/A-48-44-44N/A
6/30/2018N/A-51-44-44N/A
3/31/2018N/A-54N/A-45N/A
12/31/2017N/A-56N/A-46N/A
9/30/2017N/A-55N/A-45N/A
6/30/2017N/A-52N/A-41N/A
3/31/2017N/A-46N/A-35N/A
12/31/2016N/A-36N/A-28N/A
9/30/2016N/A-31N/A-22N/A
6/30/2016N/A-24N/A-19N/A
3/31/2016N/A-36N/A-15N/A
12/31/2015N/A-31N/A-11N/A
9/30/2015N/A-25N/A-7N/A

アナリストによる今後の成長予測

収入対貯蓄率: CRVS今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: CRVS今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: CRVS今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: CRVSの収益 ( 76.9% ) US市場 ( 8.9% ) よりも速いペースで成長すると予測されています。

高い収益成長: CRVSの収益 ( 76.9% ) 20%よりも速いペースで成長すると予測されています。


一株当たり利益成長率予想


将来の株主資本利益率

将来のROE: CRVSの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です


成長企業の発掘